Table 1.
Samples | Concentrations(μg/mL) | DPPH % inhibition(mean ± S.E.M) | DPPH IC50(μg/mL) | ABTS percent inhibition(mean ± S.E.M) | ABTS IC50(μg/mL) |
---|---|---|---|---|---|
Compound V | 1000 | 82.13±1.21** | 72 | 81.21±1.31** | 74 |
500 | 72.19±1.63** | 75.93±1.81** | |||
250 | 64.15±0.94** | 63.14±2.10*** | |||
125 | 57.13. ±1.90*** | 55.15±2.51** | |||
62.5 | 48.79±3.33*** | 47.45±2.06** | |||
Compound VI | 1000 | 85.21±1.10** | 65 | 84.13±2.11** | 67 |
500 | 73.19±1.17** | 76.23±2.91** | |||
250 | 65.64±1.84** | 65.24±1.03*** | |||
125 | 56.19. ±1.18*** | 56.21±2.11** | |||
62.5 | 49.68±2.31*** | 49.18±1.26** | |||
Compound VII | 1000 | 87.41±1.20** | 64 | 86.13±2.31** | 65 |
500 | 78.49±1.17** | 77.19±2.10** | |||
250 | 69.53±1.11** | 67.14±1.10*** | |||
125 | 56.19. ±1.30*** | 57.19±1.11** | |||
62.5 | 49.72±3.01*** | 49.70±1.06** | |||
Compound VIII | 1000 | 81.64±2.76*** | 118 | 80.23±1.37** | 125 |
500 | 72.84±1.87** | 70.10±1.20** | |||
250 | 63.13±2.17** | 62.19±0.90*** | |||
125 | 51.10±2.39*** | 50.02±1.11** | |||
62.5 | 41.17±1.97*** | 41.70±1.06** | |||
Ascorbic acid | 1000 | 94.88±1.63 | 35 | 93.41±0.73 | 35 |
500 | 87.21±0.75 | 83.76±1.16 | |||
250 | 78.89±1.34 | 77.64±3.06 | |||
125 | 65.30±2.05 | 64.06±1.15 | |||
62.5 | 55.05±1.54 | 55.51±1.09 |
Notes: Data presented as mean ± S.E.M; n=3. Values significantly different as compared to positive control, P>0.05, **P<0.05, ***P<0.001. Ascorbic acid was used as a positive control.